An experimental, personalized cancer vaccine has demonstrated remarkable long-term survival in a small group of pancreatic cancer patients, offering a new glimmer of hope against one of the deadliest malignancies. Follow-up data from an early clinical trial shows that nearly 90% of patients whose immune systems responded to the vaccine were still alive up to six years after treatment, a stark contrast to the disease's typical five-year survival rate of around 13%.
The phase 1 trial tested autogene cevumeran (BNT122), a therapeutic mRNA vaccine developed by BioNTech and Genentech. For the 16 participants, the vaccine was part of a regimen that included surgery, chemotherapy, and an immunotherapy drug. The core innovation is personalization. After a patient's tumor is removed, it is genetically analyzed to create a vaccine that teaches their immune system to recognize and attack unique mutations present in their own cancer cells.
Researchers found that patients who responded to the vaccine generated a powerful and durable army of cancer-killing immune cells. Specifically, they produced CD8+ T cells that remained active for up to six years, as well as helper CD4+ T cells believed to sustain the immune response. "These early results show this new immunotherapy approach has the potential to make a difference for one of the deadliest cancers," said the trial's principal investigator, Dr. Vinod Balachandran, who presented the findings at the 2026 American Association for Cancer Research meeting.
Broader Vaccine Efforts Advance
Separately, researchers are advancing a different, "off-the-shelf" vaccine designed for the many pancreatic cancers driven by mutations in the KRAS gene. An early trial of this vaccine, called ELI-002 2P, showed it helped some patients live longer without their cancer returning. A larger phase 2 trial is expected to open soon to test this approach in more patients.
Inspired by the early success of the personalized mRNA vaccine, a global phase 2 clinical trial is now underway to test autogene cevumeran in a larger group of patients. This next step is crucial for confirming the therapy's effectiveness. For patients like Donna Gustafson, the first enrollee in the phase 1 trial over six years ago, the results have been life-changing. Now 72 and living without limitations, she calls her experience "absolutely been a miracle." As research continues, the goal remains clear: to transform pancreatic cancer from a nearly always fatal diagnosis into a manageable condition by empowering the body's own defenses.